20857-31-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyridinecarboxylic acid, 6-formyl-, ethyl ester is used as a precursor in the synthesis of pharmaceutical drugs. Its unique chemical structure allows it to be a key component in the development of new medications, contributing to the advancement of healthcare and treatment options.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Pyridinecarboxylic acid, 6-formyl-, ethyl ester serves as a component in the formulation of various products. Its inclusion in these formulations is crucial for enhancing the effectiveness of agrochemicals, thereby supporting agricultural productivity and crop protection.
Used in Flavor and Fragrance Industry:
3-Pyridinecarboxylic acid, 6-formyl-, ethyl ester is also utilized in the production of flavor and fragrance ingredients. Its distinctive chemical properties make it a valuable contributor to the creation of unique scents and tastes in a variety of consumer products, from food to cosmetics.
Used as an Intermediate in Chemical Production:
3-Pyridinecarboxylic acid, 6-formyl-, ethyl ester's ethyl ester form makes it more suitable for use as an intermediate in the production of other chemicals. Its role in chemical synthesis is essential for creating a wide array of chemical products used across different industries.

Upstream product

• 881-86-7 dimethyl 2,5-pyridine dicarboxylate 
• 100-26-5 Pyridine-2,5-dicarboxylic acid 
• 5552-44-3 ethyl 2,5-pyridinedicarboxylate 
• 35005-81-3 ethyl 6-(hydroxy-methyl)-pyrid-3-yl-carboxylate 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS

The invention provides a composition of matter which: ? (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or ? (ii) consists of at least 90 % by weight of an atropisomer (2B) and 0-10 %

PYRROLE DERIVATIVES AS PLK1 INHIBITORS

The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof. The compounds are useful in the treatment of cancers.

NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF

There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.)

High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity

We report the discovery of novel 5-HT1A receptor agonists and describe the process that led to the antidepressant candidate 9 (F 15599). 9 has nanomolar affinity for 5-HT1A binding sites and is over 1000-fold selective with respect to the other 5-HT1 receptor subtypes, 5-HT2-7 receptor families, and also numerous GPCRs, transporters, ion channels, and enzymes. In a cellular model of signal transduction, 9 activates h5-HT1A receptors with an efficacy superior to that of the prototypical 5-HT1A agonist (±)-8-OH-DPAT and comparators undergoing clinical trials. After acute oral administration in rats, 9 totally reverses immobility in the forced swimming test and produces behaviors characteristic of 5-HT1A receptor activation. However, these effects occurred at widely separated doses, suggesting that 9 discriminates between distinct populations of 5-HT1A receptors. While the clinical relevance of these observations is still unknown, this opens new perspectives for the treatment of depressive disorders.

Oxazoline antiproliferative agents

Compounds having Formula I are useful for treating cancer. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of treating cancer in a mammal.